Central Pharmaceutical CPC1 JSC

Central Pharmaceutical CPC1 JSC maintains a debt-to-equity ratio of 1.04, indicating a moderate reliance on debt financing, while its current ratio of 1.32 suggests adequate short-term liquidity to cover its obligations. However, the company's operating cash flow is negative at -142,376,622,540 VND, which raises concerns about its ability to generate sufficient cash from operations to service its debt and fund ongoing operations. Despite this, the company's free cash flow of 75,597,179,020 VND indicates that it is able to generate positive cash flow after capital expenditures, which can be used for dividends, debt repayment, or reinvestment. In terms of profitability, the company's return on equity of 19.18% and return on assets of 5.87% are strong indicators of efficient use of equity and assets to generate profits. These figures are in line with the industry's preferred metrics, which emphasize high returns on invested capital and asset efficiency. The company's gross profit of 288,837,788,630 VND and operating income of 102,047,956,840 VND further support its profitability, although the net income of 113,082,355,400 VND is slightly lower than the operating income, indicating some non-operating expenses or taxes. The company's revenue is derived from both locally produced medicines and imported medical devices and medicines. It distributes products under the trademarks of Zento B CPC1 and Medipharco, as well as imports from international brands such as ROTEXMEDICA from Germany, Tivortin from Ukraine, and Esseti Pharma from Italy. This diversification of product sources helps mitigate the risk of over-reliance on a single market or supplier. However, the company's geographic exposure is primarily concentrated in Vietnam, with its headquarters in Hanoi, and it does not disclose significant international revenue. Looking at the company's growth trajectory, the outlook for the current fiscal year and the next fiscal year is positive, with expected revenue growth driven by the expansion of its product portfolio and increased market penetration in Vietnam. The company's capital expenditure of -9,893,683,620 VND indicates a reduction in investment in new assets, which may be a strategic decision to focus on optimizing existing operations rather than expanding. This approach could help the company improve its cash flow and reduce financial risk in the short term. The company faces several risk factors, including liquidity risk due to its negative operating cash flow and the potential for dilution, although the risk of dilution is currently assessed as low. The company's total liabilities of 1,338,326,478,840 VND and long-term debt of 610,875,667,650 VND represent a significant financial burden, and the company must manage these obligations carefully to avoid financial distress. Additionally, the company's reliance on imported products exposes it to currency fluctuations and geopolitical risks, which could impact its cost structure and profitability. Recent events, including the company's 10-K filing and other disclosed financial reports, provide insight into its financial health and strategic direction. The company has not disclosed any major legal or regulatory issues, and its financial statements appear to be in compliance with accounting standards. However, the company's negative operating cash flow and high debt levels suggest that it may need to take steps to improve its financial position in the near term.